No, Amy Belt Raimundo didn’t blow anything up. But she knew early on in college that her initial career choice of chemistry wasn’t her true path. Instead, she earned an economics degree, and used insights learned to begin a stint in consulting. Those formative years led her to business school and a job at Guidant. In this podcast, Amy Belt Raimundo explains how asking the right questions at Guidant set her internal GPS toward a career in investing for venture firms, corporates, and now the most prominent healthcare system in the country.
Amy Belt Raimundo
Kaiser Permanente Ventures
Amy Belt Raimundo joined Kaiser Permanente Ventures as managing director. Amy brings over 20 years of experience in healthcare investing, start-up and corporate operations and hospital system consulting. Immediately prior to joining Kaiser, Amy was the Chief Business Officer of digital health start-up Evidation Health founded by GE Ventures and Stanford Healthcare where she led all commercial and business development activities. Previously, Amy spent close to a decade in venture capital focused on healthcare technology as a Vice President at Covidien Ventures and Advanced Technology Ventures (ATV). She led investments in Medina Medial (acquired by Medtronic) and Nevro Corporation (NYSE: NVRO) among others. Earlier in her career, Amy held operating roles at Guidant Corporation (acquired by Abbott Vascular) including leading the international launch of the Xience drug eluting stent and managing product lines across the US, Europe and Asia. She began her career as a management consultant for APM/CSC Healthcare, optimizing operations and clinical guidelines for major hospital systems. Amy is a Kauffman Venture Fellow as well as founder and president of MedtechWomen. She holds a BA in Economics from Yale University and an MBA from the University of California at Berkeley.
Meet Our Host
A follower and fan of medtech for nearly two decades, Tom Salemi is the former bureau chief, venture capital, at Elsevier Business Intelligence, where he oversaw coverage of venture investments in medtech.